News from janssen research A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Dec 06, 2015, 11:05 ET

Ibrutinib (IMBRUVICA®) Significantly Improved Progression-Free and Overall Survival Versus Chlorambucil in Patients with Treatment-Naive Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

 Data from the investigational, randomized, multi-center, open-label Phase 3 RESONATE™-2 (PCYC-1115) clinical trial show ibrutinib...

Dec 06, 2015, 11:00 ET

Daratumumab (DARZALEX™) Combined with Standard Treatment for Multiple Myeloma Produced Deep and Durable Responses in Relapsed or Refractory Patients

Janssen Research & Development, LLC announced new data from the ongoing Phase 1/2 GEN503 investigational study showing the human CD38-directed...

Nov 20, 2015, 06:58 ET

Janssen Submits INVOKAMET® XR (Canagliflozin / Metformin Hydrochloride Extended Release) for Approval by the U.S. FDA as an Adjunctive Treatment in Adults with Type 2 Diabetes

Janssen Research & Development, LLC (Janssen) announced today it has submitted to the U.S. Food and Drug Administration (FDA) a New Drug...

Nov 10, 2015, 09:00 ET

Janssen Addresses Challenges of Caregiving in Alzheimer's Disease with New Healthy Minds Videos

 A new series of videos about caregiving in Alzheimer's disease is being released today by Janssen Research & Development, LLC ("Janssen")...

Nov 05, 2015, 10:00 ET

Janssen to Showcase Growing Portfolio with More Than 40 Data Presentations at the 2015 American Society of Hematology (ASH) Annual Meeting

At the 57th American Society of Hematology (ASH) Annual Meeting, Janssen Research & Development, LLC will present new data for both approved...

Oct 28, 2015, 08:30 ET

IMBRUVICA® (ibrutinib) Awarded Prix Galien 2015 Best Pharmaceutical Agent

 Today, IMBRUVICA® (ibrutinib) was awarded the prestigious Prix Galien USA 2015 Award in the category of Best Pharmaceutical Agent. The...

Oct 19, 2015, 08:10 ET

Phase 3 Data Show STELARA® Induced Clinical Response And Remission In The Treatment Of Patients With Moderate To Severe Crohn's Disease

Phase 3 data presented for the first time showed treatment with STELARA® (ustekinumab) induced clinical response and clinical remission in...

Oct 08, 2015, 09:00 ET

Janssen Tackles Mental Health Stigma in New Healthy Minds Videos

 A new series of videos about stigma and mental illness are being released today by Janssen Research & Development, LLC ("Janssen") as part...

Sep 04, 2015, 15:29 ET

U.S. FDA Grants Priority Review to Janssen for Daratumumab as a Treatment for Multiple Myeloma

 Janssen Research & Development, LLC (Janssen) announced today the U.S. Food and Drug Administration (FDA) has accepted for Priority Review...

Aug 26, 2015, 17:11 ET

Data Published in The New England Journal of Medicine Show Single-Agent Daratumumab Demonstrated a 36 Percent Overall Response Rate and Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients

Janssen Research & Development, LLC announced today data from the multicenter, two-part, open-label Phase 1/2 GEN501 study published in The New...

Jul 08, 2015, 17:00 ET

Phase 2b Findings Published In The New England Journal Of Medicine Demonstrate Significant Efficacy Of Guselkumab In Treatment Of Moderate To Severe Plaque Psoriasis

 Results published today in The New England Journal of Medicine from a Janssen Research & Development, LLC (Janssen)-sponsored Phase...

Jun 06, 2015, 10:00 ET

New Data Show Initial Use of Canagliflozin in Combination with Metformin Extended Release Significantly Improves A1C Levels in Adults with Type 2 Diabetes

 Janssen Research & Development, LLC (Janssen) today announced results of a phase 3, randomized study showing that the use of initial...

Jun 05, 2015, 11:50 ET

Janssen Initiates Rolling Submission of Biologic License Application (BLA) for daratumumab with U.S. FDA for the Treatment of Multiple Myeloma

Janssen Research & Development, LLC (Janssen) has initiated the rolling submission of its Biologic License Application (BLA) for daratumumab to...

Jun 01, 2015, 17:00 ET

Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma

 Janssen Research & Development, LLC (Janssen) announced data from the Phase 3 multicenter study SAR3007, which demonstrated a significant...

May 30, 2015, 07:32 ET

Ibrutinib (IMBRUVICA®) HELIOS Interim Analysis Study Data Show Significant Reductions in Risk of Progression or Death in Patients with Previously-Treated Chronic Lymphocytic Leukemia

 Data from the Phase 3 CLL3001 (HELIOS) trial demonstrated that the combination of ibrutinib (IMBRUVICA®) plus bendamustine and rituximab...

May 30, 2015, 07:31 ET

Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients

 Data from the international, multi-center, open-label, two-part, single-arm Phase 2 MMY2002 (SIRIUS) trial show treatment with single-agent...

May 13, 2015, 17:09 ET

Janssen to Showcase Data from Five Compounds Including Daratumumab and IMBRUVICA at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting

Janssen Research & Development, LLC (Janssen) announced that data from five oncology treatments across the portfolio, including marketed and...

Mar 30, 2015, 08:00 ET

FDA Approves Label Update for ZYTIGA® to Include Statistically Significant Overall Survival Results in Chemotherapy-Naive Men with Metastatic Castration-Resistant Prostate Cancer

 The U.S. Food and Drug Administration (FDA) has approved a label update for ZYTIGA® (abiraterone acetate) plus prednisone based on...

Mar 16, 2015, 15:07 ET

Phase 3 Study with IMBRUVICA® (ibrutinib) Combination Demonstrates Significant Delay in Disease Progression

 Janssen Research & Development, LLC (Janssen) announced today that a pre-planned interim analysis of the Phase 3 HELIOS (CLL3001) study...

Feb 12, 2015, 06:15 ET

Janssen Sets A Course To Intercept Type 1 Diabetes Together With JDRF

Janssen Research & Development, LLC (Janssen), one of the Janssen Pharmaceutical Companies of Johnson & Johnson, announced today that it...